News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Amado Rafael
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/02/2023 |
4
| Amado Rafael (Director) has filed a Form 4 on Poseida Therapeutics, Inc.
Txns:
| Granted 39,300 shares
@ $0 Granted 55,200 options to buy
@ $2.76, valued at
$152.4k
|
|
04/05/2023 |
4
| Amado Rafael (See Remarks) has filed a Form 4 on Zai Lab Ltd
Txns:
| Granted 113,217 options to buy
@ $33.95, valued at
$3.8M
Granted 21,564 options to buy
@ $0 |
|
01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/11/2022 |
4
| Amado Rafael (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Granted 19,120 shares
@ $0 Paid exercise price by delivering 8,464 shares
@ $11.8265, valued at
$100.1k
|
|
10/05/2022 |
4
| Amado Rafael (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 8,968 shares
@ $11.0617, valued at
$99.2k
|
|
08/02/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Sold 2,000 shares
@ $11.97, valued at
$23.9k
|
|
07/06/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Sold 2,000 shares
@ $11.44, valued at
$22.9k
|
|
06/22/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Sold 2,000 shares
@ $11.18, valued at
$22.4k
|
|
05/19/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Sold 11,500 shares
@ $7.3993, valued at
$85.1k
|
|
03/25/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Granted 237,358 shares
@ $0 Granted 368,589 options to buy
@ $9.69, valued at
$3.6M
|
|
03/17/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Sold 5,169 shares
@ $7.709, valued at
$39.8k
|
|
10/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/30/2021 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Granted 24,866 shares
@ $0 Granted 92,365 options to buy
@ $33.78, valued at
$3.1M
|
|
03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/20/2020 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Granted 30,800 shares
@ $0 Granted 109,600 options to buy
@ $18.22, valued at
$2M
|
|
09/05/2019 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.
Txns:
| Granted 105,162 shares
@ $0 Granted 160,630 options to buy
@ $26.15, valued at
$4.2M
|
|
08/07/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/16/2019 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns:
| Sold 3,028 shares
@ $5.3694, valued at
$16.3k
|
|
01/08/2019 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns:
| Granted 1,006,224 options to buy
@ $0 Granted 224,724 options to buy
@ $0 |
|
08/07/2018 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns:
| Granted 678,720 options to buy
@ $0 |
|
01/17/2018 |
4
| Amado Rafael (Chief Medical Officer) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns:
| Granted 859,968 options to buy
@ $0 Granted 192,060 options to buy
@ $0 |
|
01/18/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|